Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.51 |
| ▸ | BRAF | P15056 | 2/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.51 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.51 |
| ▸ | FLT1 | P17948 | 1/20 | 0.50 |
| ▸ | IDH1 | O75874 | 1/20 | 0.46 |
| ▸ | PPIA | P62937 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1347000 | 0.88 | ALDH1A1 (0.47) | KDRMEN1KMT2ALMNAMAPT | |
| SCHEMBL1347578 | 0.83 | KDR (0.55) | KDRFLT1MEN1KMT2ALMNA | |
| SCHEMBL1346852 | 0.83 | KDR (0.55) | KDRBRAFMAPK14TNNI3KFLT1 | |
| SCHEMBL1347067 | 0.80 | MAPK14 (0.48) | KDRBRAFMAPK14TNNI3KPPIA | |
| SCHEMBL1344783 | 0.80 | KDR (0.53) | KDRBRAFMAPK14TNNI3KFLT1 | |
| SCHEMBL1496280 | 0.79 | KDR (0.53) | KDRFLT1MEN1KMT2ALMNA | |
| SCHEMBL1496352 | 0.79 | BLK (0.51) | KDRFLT1KMT2ALMNAALDH1A1 | |
| SCHEMBL1496284 | 0.79 | KDR (0.52) | KDRFLT1MEN1KMT2AALDH1A1 | |
| SCHEMBL1496290 | 0.78 | NPC1 (0.55) | KDRMEN1KMT2ARXFP1LMNA | |
| SCHEMBL1496291 | 0.77 | KDM4E (0.47) | KDRMEN1KMT2ALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063034-B2 | Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-22 | — | — | US | disclosed |
| US-8063034-B2 | Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-22 | — | — | US | disclosed |
| US-8063034-B2 | Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-22 | — | — | US | disclosed |
| US-20100016354-A1 | NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100016354-A1 | NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100016354-A1 | NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128156-A1 | NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITING ACTIVITY | Santen Pharmaceutical Co., Ltd (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016354-A1 | NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY | FLT4, VEGFA, FLT1 | KDR 4/4885BRAF 266/4885MAPK14 2171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.